Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2026)

Rani Therapeutics Holdings' Interest Expenses history runs 7 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 157.37% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 64.11% decrease from a year earlier, with the FY2025 full-year figure at $79.1 million, up 1470.77% from the prior year.
• Interest Expenses advanced to $2.4 million in Q1 2026 per RANI's latest filing, from $476000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $6.7 million in Q3 2024 and bottomed at $378000.0 in Q4 2022.
• The 5-year median for Interest Expenses is $1.3 million (2023), against an average of $2.1 million.
• Biggest YoY gain for Interest Expenses was 2919.68% in 2022; the steepest drop was 94.97% in 2022.
• Year by year, Interest Expenses stood at $378000.0 in 2022, then soared by 800.0% to $3.4 million in 2023, then slumped by 66.96% to $1.1 million in 2024, then slumped by 57.65% to $476000.0 in 2025, then soared by 409.87% to $2.4 million in 2026.
• Per Business Quant, the three latest RANI Interest Expenses figures stand at $2.4 million (Q1 2026), $476000.0 (Q4 2025), and $4.8 million (Q3 2025).